#3080
Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
Introduction:
Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Apostolidis L,
Starke H,
Bhatti I,
Jäger D,
Winkler E,
Keywords:
NEN G3,
neuroendocrine carcinoma,
adjuvant,
neoadjuvant,
surgery,
#2259
Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma
Introduction:
Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Apostolidis L,
Nientiedt C,
Winkler E,
Stenzinger A,
Duensing S,
Keywords:
neuroendocrine carcinoma,
prostate,
chemotherapy,
immunotherapy,
#2250
Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction:
Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Apostolidis L,
Bergmann F,
Haag G,
Jäger D,
Winkler E,
Keywords:
MiNEN,
mixed neuroendocrine non-neuroendocrine neoplasm,
MANEC,
mixed adenoneuroendocrine carcinoma,
#2090
Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?
Introduction:
Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Winkler E,
Mehlis K,
Kudlich M,
Apostolidis L,
Witte J,
Keywords:
financial toxicity,
economic burden,
patient-reported outcome,
distress,
quality of life,
